Regulus

The funding coincides with publication of reports from the Extracellular RNA Consortium outlining growth and challenges in exosomal RNA-based diagnostics.

The company provided updates for its hepatitis C and Alport syndrome candidates, which are both set to enter Phase II testing this year.

The data also point to viral load reductions regardless of disease genotype, extent of patient liver fibrosis, or failure with other treatments.

Regulus said it was able to develop its miRNA extraction and profiling technology to meet the quality specifications set out by its partner.

The delivery approach has gained traction in recent years and is being explored by a number of RNA drug firms.

The data show that RG-012 can enhance the effect of Sanofi's kidney protectant ramipril and suggest the microRNA drug might have use in other chronic kidney diseases.

NEW YORK (GenomeWeb) — October was a turbulent month on Wall Street for several key RNAi/microRNA players, with two companies — Regulus Therapeutics and Alnylam Pharmaceuticals — seeing major gains on encouraging clinical data and two others — Arrowhead Research and Tekmira Pharmaceuticals — taki

NEW YORK (GenomeWeb) — Buoyed by positive Phase I data on its microRNA-targeting hepatitis C drug RG-101, Regulus Therapeutics is aiming to begin Phase II testing of the dr

NEW YORK (GenomeWeb) — Regulus Therapeutics announced this week that it has closed its previously announced public stock offering, raising $103.5 million through the transaction.

NEW YORK (GenomeWeb) — Regulus Therapeutics this week announced that it had priced its previously announced public offering of roughly 5.3 million shares of its common stock at $17 apiece, valuing the transaction at about $90 million.

Pages

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.